Tumor CDKN2A-Associated JAK2 Loss and Susceptibility to Immunotherapy Resistance.

Abstract excerpt

Poor clinical responses to checkpoint blockade with anti-CTLA-4 and anti-PD-1 antibodies in melanoma have recently been associated with acquired IFNγ resistance that protects tumor cells from the antiproliferative and pro-apoptotic cytokine activity. IFNγ-resistant melanoma cells very often lack functional expression of the IFNγ signaling pathway gene JAK2 due to gene deletions or inactivating gene mutations....

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cyclin-Dependent Kinase Inhibitor p16
• Share to Genes, Tumor Suppressor